| Product Unit Size | Cost | Quantity | Stock |
|---|
Oseltamivir is an antiviral compound that is used clinically to treat influenza infection. Oseltamivir covalently inhibits viral neuraminidase. This compound may also inhibit monoamine oxidase A (MAO-A), increasing dopamine levels in the brain.
| Cas No. | 204255-11-8 |
|---|---|
| Purity | ≥98% |
| Formula | C16H28N2O4 • H3PO4 |
| Formula Wt. | 410.4 |
| IUPAC Name | ethyl (3R,4R, 5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate; phosphoric acid |
| Appearance | White Crystal Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Huang L, Cao Y, Zhou J, et al. A conformational restriction in influenza A virus neuraminidase binding site by R152 caused the combinational effect of I222T with H274Y on oseltamivir resistance. Antimicrob Agents Chemother. 2013 Dec 23. [Epub ahead of print]. PMID: 24366752.
Vavricka CJ, Liu Y, Kiyota H, et al. Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. Nat Commun. 2013;4:1491. PMID: 23422659.
Hiasa M, Isoda Y, Kishimoto Y, et al. Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir. Br J Pharmacol. 2013 May;169(1):115-29. PMID: 23320399.
Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965. PMID: 22258996.